Cargando…

Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior

PURPOSE/BACKGROUND: Numerous health authority approvals of esketamine nasal spray, combined with oral antidepressant, to treat depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior were based on 2 identically designed, double-blind, phase 3 studies. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Canuso, Carla M., Ionescu, Dawn F., Li, Xiang, Qiu, Xin, Lane, Rosanne, Turkoz, Ibrahim, Nash, Abigail I., Lopena, Tricia J., Fu, Dong-Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Original Contributions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8407443/ https://www.ncbi.nlm.nih.gov/pubmed/34412104 http://dx.doi.org/10.1097/JCP.0000000000001465

Ejemplares similares

Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)
por: Ionescu, Dawn F, et al.
Publicado: (2020)

Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II)
por: Jamieson, Carol, et al.
Publicado: (2023)

Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression
por: Katz, Eva G., et al.
Publicado: (2020)

Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality
por: Fu, Dong-Jing, et al.
Publicado: (2023)

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
por: Chen, Guang, et al.
Publicado: (2022)

Assessing the meaningful change threshold of Quality of Life in Depression Scale using data from two phase 3 studies of esketamine nasal spray
por: Rozjabek, Heather, et al.
Publicado: (2022)

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA
por: Chen, Xu, et al.
Publicado: (2023)

Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
por: Jones, Robyn R., et al.
Publicado: (2022)

Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials
por: Diekamp, Bettina, et al.
Publicado: (2021)

Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
por: Zaki, Naim, et al.
Publicado: (2023)

The use of esketamine in the treatment of patients with severe depression and suicidal ideation: systematic review and meta-analysis
por: Floriano, Idevaldo, et al.
Publicado: (2023)

Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis
por: Wang, Sheng-Min, et al.
Publicado: (2021)

Suicide‐specific mortality among patients with treatment‐resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder alone
por: Kern, David M., et al.
Publicado: (2023)

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
por: Doherty, Teodora, et al.
Publicado: (2020)

The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder
por: Daly, Ella J., et al.
Publicado: (2021)

Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
por: Doty, Richard L., et al.
Publicado: (2021)

Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
por: Castro, Meredith, et al.
Publicado: (2023)

ESKALE study, a French real-world study of esketamine nasal spray for patients with treatment-resistant depression
por: Ludovic, S., et al.
Publicado: (2022)

The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial
por: Liu, Haiyan, et al.
Publicado: (2022)

Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment
por: Dold, Markus, et al.
Publicado: (2020)

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
por: Fedgchin, Maggie, et al.
Publicado: (2019)

Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations
por: Young, Allan H, et al.
Publicado: (2023)

Intranasal Esketamine and Current Suicidal Ideation With Intent in Major Depression Disorder: Beat the Clock, Save a Life, Start a Strategy
por: Pompili, Maurizio
Publicado: (2020)

Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial
por: Lan, Xiaofeng, et al.
Publicado: (2023)

Neural Correlates of Suicidal Ideation and Its Reduction in Depression
por: Ballard, Elizabeth D., et al.
Publicado: (2015)

At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study
por: Cepeda, M. Soledad, et al.
Publicado: (2021)

Plasma VEGF Concentrations and Ketamine's Effects on Suicidal Ideation in Depression With Suicidal Ideation
por: Zheng, Wei, et al.
Publicado: (2022)

SUICIDAL IDEATION AND BIOGENIC AMINES IN DEPRESSION*
por: Palaniappan, V., et al.
Publicado: (1983)

Treating suicidal ideation in the context of depression
por: Schneider, Renee A., et al.
Publicado: (2020)

Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
por: Jamieson, Carol, et al.
Publicado: (2023)

Commentary on Cochrane review: “Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder”
por: Borentain, Stephane, et al.
Publicado: (2022)

Managing dissociative symptoms following the use of esketamine nasal spray: a case report
por: Pereira, Sophia, et al.
Publicado: (2020)

Burnout, depression and suicidal ideation in dental students
por: Galán, Fernando, et al.
Publicado: (2014)

Critical appraisal of major depression with suicidal ideation
por: Pompili, Maurizio
Publicado: (2019)

Social determinants and distance from certified treatment centers are associated with initiation of esketamine nasal spray among patients with challenging-to-treat major depressive disorder
por: Liberman, Joshua, et al.
Publicado: (2023)

The Relationship between Depressive Symptoms, Rumination, and Suicide Ideation in Patients with Depression
por: Chiang, Yi-Hsuan, et al.
Publicado: (2022)

Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report
por: Vendrell-Serres, Júlia, et al.
Publicado: (2021)

Urothelial toxicity of esketamine in the treatment of depression
por: Findeis, Hannelore, et al.
Publicado: (2020)

Esketamine/ketamine for treatment-resistant depression
por: Lacerda, Acioly L.T.
Publicado: (2020)

Esketamine hydrochloride for treatment-resistant depression
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nnrgpo9gn3fjagk2ggqiu1a6tl